-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明，无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Comparing Better Therapeutics (BTTX) and Its Peers
Comparing Better Therapeutics (BTTX) and Its Peers
Better Therapeutics (NASDAQ:BTTX – Get Rating) is one of 33 public companies in the "Health services" industry, but how does it compare to its peers? We will compare Better Therapeutics to similar companies based on the strength of its earnings, profitability, analyst recommendations, dividends, institutional ownership, risk and valuation.
Institutional and Insider Ownership
7.5% of Better Therapeutics shares are owned by institutional investors. Comparatively, 48.6% of shares of all "Health services" companies are owned by institutional investors. 59.4% of Better Therapeutics shares are owned by insiders. Comparatively, 21.6% of shares of all "Health services" companies are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Get Better Therapeutics alerts:Analyst Ratings
This is a summary of current ratings and price targets for Better Therapeutics and its peers, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Better Therapeutics | 0 | 0 | 2 | 0 | 3.00 |
| Better Therapeutics Competitors | 7 | 131 | 277 | 0 | 2.65 |
Profitability
This table compares Better Therapeutics and its peers' net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Better Therapeutics | N/A | -200.73% | -114.68% |
| Better Therapeutics Competitors | -325.87% | -676.77% | -37.31% |
Earnings and Valuation
This table compares Better Therapeutics and its peers gross revenue, earnings per share and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Better Therapeutics | $10,000.00 | -$40.33 million | -0.70 |
| Better Therapeutics Competitors | $1.36 billion | -$98.47 million | 27.18 |
Better Therapeutics' peers have higher revenue, but lower earnings than Better Therapeutics. Better Therapeutics is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.
Risk and Volatility
Better Therapeutics has a beta of 1.36, meaning that its share price is 36% more volatile than the S&P 500. Comparatively, Better Therapeutics' peers have a beta of 1.19, meaning that their average share price is 19% more volatile than the S&P 500.
Summary
Better Therapeutics beats its peers on 8 of the 12 factors compared.
About Better Therapeutics
(Get Rating)
Better Therapeutics, Inc., a prescription digital therapeutics company, develops a form of cognitive behavioral therapy to address the causes of cardiometabolic diseases. The company develops software-based prescription digital therapeutics platform candidates for treating diabetes, heart disease, and other cardiometabolic conditions. Its clinical development candidates are intended to treat cardiometabolic diseases, including type 2 diabetes, hypertension, hyperlipidemia, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, and chronic kidney disease. The company's lead product candidate is BT-001, an investigational PDT platform to treat type 2 diabetes. Better Therapeutics, Inc. was founded in 2015 and is headquartered in San Francisco, California.
Receive News & Ratings for Better Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Better Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
Better Therapeutics (NASDAQ:BTTX – Get Rating) is one of 33 public companies in the "Health services" industry, but how does it compare to its peers? We will compare Better Therapeutics to similar companies based on the strength of its earnings, profitability, analyst recommendations, dividends, institutional ownership, risk and valuation.
Better Treateutics(纳斯达克：BTTX-GET评级)是“健康服务”行业的33家上市公司之一，但与其同行相比如何？我们将根据其收益、盈利能力、分析师建议、股息、机构所有权、风险和估值的实力，将Better Treateutics与类似公司进行比较。
Institutional and Insider Ownership
机构和内部人持股
7.5% of Better Therapeutics shares are owned by institutional investors. Comparatively, 48.6% of shares of all "Health services" companies are owned by institutional investors. 59.4% of Better Therapeutics shares are owned by insiders. Comparatively, 21.6% of shares of all "Health services" companies are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Better Treateutics 7.5%的股份由机构投资者持有。相比之下，所有“健康服务”公司48.6%的股份由机构投资者持有。Better Treateutics 59.4%的股份由内部人士持有。相比之下，所有“健康服务”公司21.6%的股份由内部人持有。强大的机构持股表明，捐赠基金、对冲基金和大型基金管理公司相信，一只股票的长期表现将好于大盘。
Analyst Ratings
分析师评级
This is a summary of current ratings and price targets for Better Therapeutics and its peers, as reported by MarketBeat.
据MarketBeat报道，这是对Better Treateutics及其同行的当前评级和价格目标的摘要。
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Better Therapeutics | 0 | 0 | 2 | 0 | 3.00 |
| Better Therapeutics Competitors | 7 | 131 | 277 | 0 | 2.65 |
| 销售评级 | 保持评级 | 购买评级 | 强劲的买入评级 | 评级分数 | |
| 更好的治疗学 | 0 | 0 | 2 | 0 | 3.00 |
| Better Treateutics的竞争对手 | 7 | 131 | 277 | 0 | 2.65 |
Profitability
盈利能力
This table compares Better Therapeutics and its peers' net margins, return on equity and return on assets.
此表比较了Better Treeutics及其同行的净利润率、股本回报率和资产回报率。
| Net Margins | Return on Equity | Return on Assets | |
| Better Therapeutics | N/A | -200.73% | -114.68% |
| Better Therapeutics Competitors | -325.87% | -676.77% | -37.31% |
| 净利润率 | 股本回报率 | 资产回报率 | |
| 更好的治疗学 | 不适用 | -200.73% | -114.68% |
| Better Treateutics的竞争对手 | -325.87% | -676.77% | -37.31% |
Earnings and Valuation
收益和估值
This table compares Better Therapeutics and its peers gross revenue, earnings per share and valuation.
此表比较了Better Treateutics及其同行的毛收入、每股收益和估值。
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Better Therapeutics | $10,000.00 | -$40.33 million | -0.70 |
| Better Therapeutics Competitors | $1.36 billion | -$98.47 million | 27.18 |
| 总收入 | 净收入 | 市盈率 | |
| 更好的治疗学 | $10,000.00 | -4,033万元 | -0.70 |
| Better Treateutics的竞争对手 | 13.6亿美元 | -9,847万元 | 27.18 |
Better Therapeutics' peers have higher revenue, but lower earnings than Better Therapeutics. Better Therapeutics is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.
Better Treateutics的同行有更高的收入，但收入比Better Treateutics低。Better Treateutics的市盈率低于同行，这表明它目前比行业内的其他公司更负担得起。
Risk and Volatility
风险和波动性
Better Therapeutics has a beta of 1.36, meaning that its share price is 36% more volatile than the S&P 500. Comparatively, Better Therapeutics' peers have a beta of 1.19, meaning that their average share price is 19% more volatile than the S&P 500.
Better Treateutics的贝塔系数为1.36，这意味着其股价的波动性比标准普尔500指数高36%。相比之下，Better Treateutics的贝塔系数为1.19，这意味着它们的平均股价波动性比标准普尔500指数高19%。
Summary
摘要
Better Therapeutics beats its peers on 8 of the 12 factors compared.
Better Treateutics在比较的12个因素中有8个超过了同行。
About Better Therapeutics
关于Better Treatetics
(Get Rating)
(获取评级)
Better Therapeutics, Inc., a prescription digital therapeutics company, develops a form of cognitive behavioral therapy to address the causes of cardiometabolic diseases. The company develops software-based prescription digital therapeutics platform candidates for treating diabetes, heart disease, and other cardiometabolic conditions. Its clinical development candidates are intended to treat cardiometabolic diseases, including type 2 diabetes, hypertension, hyperlipidemia, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, and chronic kidney disease. The company's lead product candidate is BT-001, an investigational PDT platform to treat type 2 diabetes. Better Therapeutics, Inc. was founded in 2015 and is headquartered in San Francisco, California.
Better Treateutics，Inc.，一家处方数字治疗公司，开发了一种认知行为疗法，以解决心脏代谢性疾病的原因。该公司开发基于软件的处方数字疗法平台，用于治疗糖尿病、心脏病和其他心脏代谢疾病。其临床开发候选药物旨在治疗心脏代谢性疾病，包括2型糖尿病、高血压、高脂血症、非酒精性脂肪性肝病、非酒精性脂肪性肝炎和慢性肾脏疾病。该公司的主要候选产品是BT-001，这是一种治疗2型糖尿病的研究PDT平台。Better Treateutics，Inc.成立于2015年，总部位于加利福尼亚州旧金山。
Receive News & Ratings for Better Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Better Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
每天收到更好的治疗新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯，接收最新新闻和分析师对Better Treateutics和相关公司的评级的每日摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能，分享给你的好友吧